Background-Catecholamines hasten cardiac relaxation through ␤-adrenergic receptors, presumably by phosphorylation of several proteins, but it is unknown which receptor subtypes are involved in human ventricle. We assessed the role of ␤ 1 -and ␤ 2 -adrenergic receptors in phosphorylating proteins implicated in ventricular relaxation. Methods and Results-Right ventricular trabeculae, obtained from freshly explanted hearts of patients with dilated cardiomyopathy (nϭ5) or ischemic cardiomyopathy (nϭ5), were paced at 60 bpm. After measurement of the contractile and relaxant effects of epinephrine (10 mol/L) or zinterol (10 mol/L), mediated through ␤ 2 -adrenergic receptors, and of norepinephrine (10 mol/L), mediated through ␤ 1 -adrenergic receptors, tissues were freeze clamped. We assessed phosphorylation of phospholamban, troponin I, and C-protein, as well as specific phosphorylation of phospholamban at serine 16 and threonine 17. Data did not differ between the 2 disease groups and were therefore pooled. Epinephrine, zinterol, and norepinephrine increased contractile force to approximately the same extent, hastened the onset of relaxation by 15Ϯ3%, 5Ϯ2%, and 20Ϯ3%, respectively, and reduced the time to half-relaxation by 26Ϯ3%, 21Ϯ3%, and 37Ϯ3%. These effects of epinephrine, zinterol, and norepinephrine were associated with phosphorylation (pmol phosphate/mg protein) of phospholamban 14Ϯ3, 12Ϯ4, and 12Ϯ3; troponin I 40Ϯ7, 33Ϯ7, and 31Ϯ6; and C-protein 7.2Ϯ1.9, 9.3Ϯ1.4, and 7.5Ϯ2.0. Phosphorylation of phospholamban occurred at both Ser16 and Thr17 residues through both ␤ 1 -and ␤ 2 -adrenergic receptors. Conclusions-Norepinephrine and epinephrine hasten human ventricular relaxation and promote phosphorylation of implicated proteins through both ␤ 1 -and ␤ 2 -adrenergic receptors, thereby potentially improving diastolic function. (Circulation. 1999;99:65-72.)
A ctivation of cardiac ␤-adrenergic receptors by catecholamines augments contractility and hastens relaxation. Catecholamines are thought to promote relaxation (ie, cause lusitropic effects) 1 by inducing the phosphorylation, catalyzed by cAMP-dependent protein kinase A (PKA), of at least 2 proteins, phospholamban [1] [2] [3] and troponin I, 4 and perhaps of C-protein. 5, 6 Phospholamban can also be phosphorylated by a Ca 2ϩ /calmodulin-dependent protein kinase 7 (CaM kinase). Nonphosphorylated phospholamban exerts a braking effect on the Ca 2ϩ ATPase that pumps Ca 2ϩ into the sarcoplasmic reticulum. 3 Phospholamban phosphorylation results in liberation of Ca 2ϩ ATPase activity, which accelerates its pumping activity, thereby decreasing Ca 2ϩ concentrations at the contractile proteins and hastening myocyte relaxation. [1] [2] [3] Phosphorylation of troponin I desensitizes contractile proteins to Ca 2ϩ , thus providing another mechanism for relaxation. 4, 8, 9 Diastolic function deteriorates in congestive heart failure, 10 even when systolic function is unimpaired. 11 Relaxation of ventricular myocardium is retarded in heart failure and correlates with prolongation of calcium transients, suggesting a decreased capacity to restore low basal Ca 2ϩ levels. 12 One factor that correlates with the prolongation of calcium transients is deficient generation of cAMP, which is observed in heart failure. 13 Although it has been reported that phosphorylation of phospholamban, troponin I, and C-protein is decreased in failing human ventricle compared with normal myocardium, 14 positive lusitropic responses to the catecholamine dobutamine are still observed in patients with heart failure. 15 The affinity 16 and agonist potency 17 of dobutamine are similar at both ␤ 1 -and ␤ 2 -adrenergic receptors, and it is unknown which subtype is involved. We therefore sought to determine whether both ␤ 1 -and ␤ 2 -adrenergic receptors can mediate positive lusitropic effects and whether implicated proteins are phosphorylated. This is not the case in a variety of animal models in which ␤ 1 -but not ␤ 2 -adrenergic receptors mediate hastening of ventricular relaxation. 18 -23 However, there is evidence in human atrium 24, 25 and human ventricular myocytes from normal and failing hearts 26 that both ␤ 1 -and ␤ 2 -adrenergic receptors mediate not only inotropic but also lusitropic effects. We now confirm this in ventricular trabeculae from failing ischemic and cardiomyopathic hearts and show it to be associated with phosphorylation of phospholamban, troponin I, and C-protein for both ␤ 1 -and ␤ 2 -adrenergic receptors.
Methods

Patients
Informed consent was obtained from all patients (Table 1 ). All patients had terminal heart failure and underwent cardiac transplant surgery. This study was approved by the ethics committees of the Papworth Hospital, Cambridgeshire (United Kingdom), and Alfred Hospital, Melbourne (Australia).
Isolated Right Ventricular Trabecula Carnae
Explanted hearts were obtained immediately (Ͻ1 minute) after removal from the patient. The endocardial layer of the right ventricular free wall was rapidly dissected in ice-cold, preoxygenated (95% O 2 -5% CO 2 1, and EDTA 0.04 at the surgical theater. Trabeculae (width usually Ͻ1 and not Ͼ1.3 mm) were dissected, set up at optimum length, and paced to contract isometrically at 60 bpm at 37°C in a bath containing the above solution supplemented with (mmol/L) Na ϩ 15, fumarate 5, pyruvate 5, L-glutamate 5, and glucose 10 as described. 27 In all experiments, contractile force and its first derivative were recorded simultaneously. Cross-sectional area of trabeculae that were not snap-frozen was determined from the length and weight of the muscle at the end of the experiment, assuming a density of 1.063. Rapid freezing of trabeculae prevented measurements of length and weight under conditions of contraction.
Specific Activation of ␤ 1 -and ␤ 2 -Adrenergic Receptors
To irreversibly block tissue uptake of catecholamines and ␣-adrenergic receptors, trabeculae were incubated for 90 minutes with phenoxybenzamine followed by washout. 28 To establish conditions for selective activation of ␤ 1 -and ␤ 2 -adrenergic receptors, experiments were carried out as described previously on ventricular preparations from hearts without advanced failure 27 and ventricular myocytes from a donor heart and hearts in terminal failure. 26 To determine ␤ 1 -selective activation, inotropic concentration-effect curves to (Ϫ)-norepinephrine in the presence of ICI118551 (50 nmol/L) (to selectively block ␤ 2 -adrenergic receptors) were determined in the absence and presence of the ␤ 1 -selective blocker CGP20712A. 24 -27 For ␤ 2 -selective activation, inotropic concentration-effect curves to (Ϫ)-epinephrine in the presence of CGP20712A (300 nmol/L) were determined in the absence and presence of ICI118551 (50 nmol/L). 24 -27 In these studies, only a single concentration-effect curve was determined on each trabeculum. After equilibrium effects were reached with the highest catecholamine concentration, (Ϫ)-isoproterenol was added at a concentration (200 mol/L) that surmounts 27 the blockade caused by CGP20712A and ICI118551. The experiments were terminated by increasing the CaCl 2 concentration to 9.25 mmol/L in the presence of catecholamines. In 4 additional patients, the effects of 9.25 mmol/L CaCl 2 were also investigated in the absence of catecholamines but in the presence of CGP20712A.
To determine relaxation and protein phosphorylation mediated by ␤ 1 -adrenergic receptors, trabeculae were exposed for 2 hours to ICI118551 (50 nmol/L) followed by incubation for 5 minutes with 10 mol/L (Ϫ)-norepinephrine. To assess ␤ 2 -adrenergic receptormediated effects for tissues from the same patient, trabeculae exposed for 2 hours to CGP20712A (300 nmol/L) were incubated for 5 minutes with 10 mol/L (Ϫ)-epinephrine or 10 mol/L zinterol. To assess maximal effects mediated through both ␤ 1 -and ␤ 2 -adrenergic receptors, CGP20712A-treated trabeculae were exposed for 5 minutes to 200 mol/L (Ϫ)-isoproterenol. Basal protein phosphorylation was determined in trabeculae from the same patient incubated with either CGP20712A or ICI118551 but not agonist.
Processing of Trabeculae for Protein Phosphorylation and Immunodetection
Freeze-clamped tissue derived from contracting trabeculae was homogenized in a histidine buffer containing NaF 25 mmol/L and phenylmethanesulfonyl fluoride 100 mol/L as described. 29 The homogenates were centrifuged at 100 000g; the pellet contained phospholamban, and the supernatant contained troponin I and C-protein.
Protein Phosphorylation
The method used, back-phosphorylation, has previously been described 29 and adapted to human cardiac tissue. 14, 25 The phosphorylation reaction was started by the addition of [␥-
32 P]ATP and the catalytic subunit of cAMP-dependent protein kinase. We used 30 g of protein per assay. After 5 minutes of incubation, the reaction was terminated with trichloroacetic acid, the resulting pellets were solubilized and boiled, and proteins were separated by PAGE. 29 Radioactive bands corresponding to phospholamban, troponin I, and C-protein were identified according to molecular mass and by immunodetection. 14 The calculated difference in 32 P incorporation between control and agonist-treated trabeculae was considered to reflect agonist-induced endogenous phosphate incorporation into the intact trabeculae and is expressed as picomoles of phosphate per 1 mg protein. Protein was determined 30 with BSA as the standard.
Site-Specific Western Blot Analysis of Phospholamban
Specific antibodies against phospholamban phosphoserine 16 and phospholamban phosphothreonine 17 were used as reported. 31 Crude membrane fractions were solubilized at room temperature in a lysis buffer containing SDS. Blots were incubated with antibodies raised against a synthetic oligopeptide sequence of phospholamban with either a phosphorylated serine 16 or threonine 17 residue 31 and visualized with an enhanced chemiluminescence-based detection system. To demonstrate the specificity of the immunological reaction, the procedures were also performed in the presence of 0.1 mol/L of the corresponding 11-amino-acid-residue oligopeptides of phospholamban, phosphorylated at either Ser16 or Thr17.
Statistical Analysis
Data are expressed as sample meanϮSE. Student's paired t test or 1-way ANOVA followed by the Bonferroni method was used for multiple comparisons by use of InStat (GraphPad software version 2.0). We used PϽ0.05 as the limit for statistical significance.
Results
Positive Inotropic and Lusitropic Effects Mediated
Through ␤ 1 -and ␤ 2 -Adrenergic Receptors (Ϫ)-Norepinephrine caused positive inotropic effects in the presence of the ␤ 2 -selective blocker ICI118551 that were antagonized with high potency by the ␤ 1 -selective blocker CGP20712A. The threshold concentrations of (Ϫ)-norepinephrine to increase contractile force were 300 nmol/L and 60 mol/L in the absence and presence of CGP20712A (300 nmol/L), respectively, and were therefore mostly mediated through ␤ 1 -adrenergic receptors. (Ϫ)-Epinephrine caused positive inotropic effects in the presence of the ␤ 1 -selective blocker CGP20712A that were antagonized by the ␤ 2 -selective ICI118551. The threshold concentrations of (Ϫ)-epinephrine were 60 nmol/L and 20 mol/L in the absence and presence of ICI118551 (50 nmol/L), respectively, consistent with mediation through ␤ 2 -adrenergic receptors. These results from hearts in terminal failure (data from 22 trabeculae of patients 1 through 3 of Table 1 ; not shown) agree with previous data from ventricular tissue from hearts in mild failure 27 and ventricular myocytes. 26 To obtain robust phosphorylation signals, we selected a relatively high catecholamine concentration, 10 mol/L, which, however, under the conditions of the present and previous studies, 26, 27 is receptor subtype-specific and produces nearly maximal effects through ␤ 1 -or ␤ 2 -adrenergic receptors. Marked positive inotropic and lusitropic effects of (Ϫ)-norepinephrine and (Ϫ)-epinephrine, mediated through ␤ 1 -and ␤ 2 -adrenergic receptors, respectively, were similar to those of (Ϫ)-isoproterenol (Figures 1 and 2 ). Zinterol, a ␤ 2 -selective partial agonist effective in human ventricle 32 and atrium, 25 also caused positive inotropic and lusitropic effects, but the lusitropic effects tended to be smaller than those of the catecholamines (Figures 1 and 2 ) and the onset of response tended to be slower than with catecholamines ( Figure 1 ).
Comparison of Inotropic and Lusitropic Potencies of (؊)-Norepinephrine and (؊)-Epinephrine Through ␤ 1 -and ␤ 2 -Adrenergic Receptors
To compare the inotropic and lusitropic potency of (Ϫ)-norepinephrine through ␤ 1 -adrenergic receptors with the corresponding potencies of (Ϫ)-epinephrine through ␤ 2 -adrenergic receptors, we determined concentration-effect curves for the 2 catecholamines under receptor-selective conditions. The lusitropic potencies of both (Ϫ)-norepinephrine and (Ϫ)-epinephrine were significantly greater than the corresponding inotropic potencies ( Figure 3 and Table 2 ).
High Ca 2؉ Does Not Hasten Relaxation
High extracellular calcium concentration has been shown to abbreviate the duration of Ca 2ϩ transients in canine cardiomyocytes 23 and to hasten relaxation in guinea pig cardiomyocytes. 33 To examine the effects of a high Ca 2ϩ concentration, we compared the effects of 9.25 mmol/L CaCl 2 with those of basal conditions (2.25 mmol/L) in trabeculae from patients 8 and 15 through 17 in Table 1 . Increasing extracellular Ca 2ϩ to 9.25 mmol/L failed to hasten relaxation, whereas (Ϫ)-norepinephrine, administered as a positive control, hastened relaxation (Figure 4 ). In 11 trabeculae from 4 patients, Ca 2ϩ 9.25 mmol/L increased contractile force from 1.2Ϯ0.4 (SE from 4 patients) to 6.6Ϯ2.0 mN/mm 2 but did not change relaxation parameters. The t 50 and time to peak values were 127Ϯ7 and 126Ϯ5 ms, and 179Ϯ15 and 186Ϯ7 ms at 2.25 and 9.25 mmol/L CaCl 2 , respectively.
Phosphorylation of Phospholamban, Troponin I, and C-Protein
Both ␤ 1 -and ␤ 2 -adrenergic agonists reduced the capacity of tissues to incorporate 32 P-phosphate into phospholamban, troponin I, and C-protein in vitro, as assessed after backphosphorylation and shown representatively in Figure 5 . This result indicates a higher endogenous phosphorylation state of each protein in the intact tissue after 5 minutes of exposure to the agonists compared with that of non-agonist-exposed tissues. The amount of protein phosphorylation in the intact ventricular trabeculae caused by the agonists was calculated from the back-phosphorylation reaction. (Ϫ)-Norepinephrine, (Ϫ)-epinephrine, and (Ϫ)-isoproterenol caused similar phosphorylation of phospholamban, troponin I, and C-protein through ␤ 1 -, ␤ 2 -, or ␤ 1 -plus ␤ 2 -adrenergic receptors, respectively ( Figure 6 ). Zinterol also induced phosphorylation of the 3 proteins through ␤ 2 -adrenergic receptors ( Figure 6 ).
Site-Specific Phosphorylation of Phospholamban
Both (Ϫ)-norepinephrine and (Ϫ)-epinephrine induced sitespecific phosphorylation of Ser16 and Thr17 residues of phospholamban through ␤ 1 -(2 patients) and ␤ 2 -adrenergic receptors (5 patients), respectively (Figure 7) , as demonstrated in competition assays with synthetic phosphooligopeptides ( Figure 7) . The (Ϫ)-epinephrine-evoked phosphorylation of phospholamban at both Ser16 and Thr17 was prevented by ICI118551 (50 nmol/L) (Western blots from 1 patient; not shown).
A trabeculum of 1 patient (patient 8 in Table 1 ) was exposed to high Ca 2ϩ (9.25 mmol/L), which increased contractile force (basal, Ca 2ϩ 2.25 mmol/L) from 1.4 to 10.5 mN but did not shorten the t 50 of relaxation, shorten the time to the onset of relaxation, or produce phosphorylation at Ser16 or Thr17 of phospholamban (not shown).
Discussion
Both ␤ 1 -and ␤ 2 -Adrenergic Receptors Hasten Relaxation Through cAMP Pathways
Our results show that both the ␤ 1 -and ␤ 2 -adrenergic receptors mediate hastening of relaxation of human ventricular myocardium, consistent with an involvement of cAMP-dependent pathways for both receptors. (Ϫ)-Norepinephrine and (Ϫ)-epinephrine had similar lusitropic potencies through ␤ 1 -and ␤ 2 -adrenergic receptors, respectively, and the lusitropic intrinsic activity of (Ϫ)-epinephrine was nearly that of (Ϫ)-nor- epinephrine. As expected from cAMP pathways, the PKA substrates implicated in relaxation, [1] [2] [3] [4] [5] [6] Ser16 phospholamban, troponin I, and C-protein were phosphorylated by (Ϫ)-norepinephrine through ␤ 1 -adrenergic receptors and by (Ϫ)-epinephrine and zinterol through ␤ 2 -adrenergic receptors. These findings are at variance with evidence in all other species studied so far (cat, sheep, rat, dog), 18 -23 in which ␤ 2 -adrenergic receptors, unlike ␤ 1 -adrenergic receptors, appear reluctant to couple to the cAMP pathway that hastens relaxation, and stress the importance of direct work on human myocardium.
Species-dependent differences between the functions of ␤ 1 -and ␤ 2 -adrenergic receptors may possibly be due to differences in coupling to the G s -protein/cAMP pathway and differential coupling to G s and G i , guanine nucleotidesensitive transducer proteins that cause activation and inhibition of the cAMP pathway, respectively. In cat heart, stimulation of the G s /cAMP pathway through ␤ 1 -and ␤ 2 -adrenergic receptors is proportional to the corresponding receptor densities, 34 suggesting similar coupling of these 2 receptors, but only ␤ 1 -adrenergic receptors hasten relaxation. 18 In contrast, human cardiac ␤ 2 -adrenergic receptors are more tightly coupled to the G s /cAMP pathway 27, 28, 35, 36 than are ␤ 1 -adrenergic receptors, and this was later confirmed with human recombinant receptors. 37, 38 The selective coupling of human ␤ 2 -adrenergic receptors probably contributes to the marked lusitropic effects of (Ϫ)-epinephrine. 36 In ventricular myocytes from nonfailing rat hearts, the ␤ 2 -adrenergic-G s /cAMP pathway leading to relaxation can be demonstrated only in the presence of pertussis toxin, 22 presumably after inactivation of functional G i . This suggests that coupling of the rat cardio- myocyte ␤ 2 -adrenergic receptor is tighter to G i than to G s . The tighter coupling of human ␤ 2 -adrenergic receptors to the G s /cAMP pathway compared with ␤ 1 -adrenergic receptors may explain why, even in failing human ventricle (this work) in which G i function and mRNA levels (G i␣a2 ) are increased, 39 -41 ␤ 2 -adrenergic receptor-mediated relaxation can still occur through the G s /cAMP pathway. It is thus possible that in nonfailing hearts with unaltered G i function, ␤ 2 -adrenergic receptors may mediate even more marked relaxant effects than in failing hearts.
One limitation of this study is that the magnitude of lusitropic effects did not correlate (not shown) with the degree of protein phosphorylation in the same ventricular preparation. Protein phosphorylation peaks may have preceded the observed lusitropic response, an issue that can be clarified only with future kinetic experiments. Our findings of significant PKA-dependent phosphorylation of phospholamban, troponin I, and C-protein through both ␤ 1 -and ␤ 2 -adrenergic receptors agree, however, with an earlier report of PKA stimulation 42 suggesting a causal relationship. Unlike the situation in many other species, 18 -23 human ventricular (this work) and atrial 25 ␤ 2 -adrenergic receptors appear to function mainly through a PKA-dependent pathway. Support for this concept has also recently been provided for the ␤ 2 -adrenergic receptor-mediated increases in L-type Ca 2ϩ current with an obligatory involvement of PKA in human atrial myocytes. 43 Zinterol increased the L-type Ca 2ϩ current and appeared to dissociate slowly from the ␤ 2 -adrenergic receptors. 43 Correspondingly, we attribute the relatively slow inotropic and lusitropic onset observed in human ventricular trabeculae (Figure 1 ) to slow equilibration of zinterol with ␤ 2 -adrenergic receptors.
The catecholamine (Ϫ)-isoproterenol can induce phosphorylation of phospholamban at both Ser16 (through PKA) and Thr17 (through CaM kinase) in rodent ventricle. 7, 44 The CaM kinase-catalyzed phosphorylation of phospholamban can contribute to increased contractility and hastened relaxation, provided dephosphorylation is negligible. 44 Type 1 phosphatase catalyzes this dephosphorylation, and the activity of type 1 phosphatase can, in turn, be inhibited by isoproterenol through PKA-catalyzed phosphorylation of protein phosphatase inhibitor-1 in guinea pig ventricular myocytes. 45 Our results show for the first time that Thr17 phosphorylation of phospholamban occurs in failing human ventricle through both ␤ 1 -and ␤ 2 -adrenergic receptors. We suggest that the CaM kinase-catalyzed phosphorylation of Thr17 of phospholamban in human ventricle can be demonstrated because its dephosphorylation is retarded by simultaneous inhibition of type 1 phosphatase by the ␤ 1 -or ␤ 2 -adrenergic receptor-mediated phosphorylation of protein phosphatase inhibitor-1. High extracellular Ca 2ϩ concentration does not appear to result in activation of sarcoplasmic reticulum CaM kinase because, in contrast to the catecholamines, it does not hasten relaxation in trabeculae from nonfailing 12 or failing hearts (Figure 4 ) and can actually prolong contractions and Ca 2ϩ transients of trabeculae from failing human ventricle. 12 In agreement with this, we have seen in the trabeculae of patient 8 in Table 1 
Possible Clinical Relevance
We have conclusively shown that (Ϫ)-epinephrine, acting through ␤ 2 -adrenergic receptors, and (Ϫ)-norepinephrine, acting through ␤ 1 -adrenergic receptors, hasten relaxation with similar potency and efficacy and cause phosphorylation of proteins implicated in the relaxation process. These results require verification in myocardium from normal hearts of donors not treated with drugs, such as ACE inhibitors. It seems reasonable, however, to suggest that diastolic function of failing heart may be improved by the action of endogenous catecholamines, mediated through both ␤ 1 -and ␤ 2 -adrenergic receptors. For example, it is conceivable that during stress endogenous plasma epinephrine surges elicit not only tachycardia but also beneficial hastening of ventricular relaxation, mediated at least partly through ␤ 2 -adrenergic receptors, thus producing a relative lengthening of diastole. Because ␤ 2 -adrenergic receptors hasten relaxation in failing human ventricular myocardium, it could be clinically desirable to selectively improve diastolic function under conditions in which ␤ 1 -adrenergic receptors are blocked. This may happen in patients with chronic heart failure undergoing treatment with ␤ 1 -selective blockers. 46 It is plausible that in these patients endogenous epinephrine may actually contribute to an improvement in diastolic function via ␤ 2 -adrenergic receptors. The likelihood of this occurring is enhanced by the observation that at least in human atrium ␤ 2 -adrenergic receptor function is increased by long-term ␤ 1 -adrenergic receptor blockade. 24 
